Prognostic significance of microRNA-200b and ERCC1 expression in tumor cells of patients with esophageal cancer
DOI:
https://doi.org/10.32471/exp-oncology.2312-8852.vol-42-no-3.14822Keywords:
aggressiveness of cancer, ERCC1, esophageal cancer, miRNA 200bAbstract
Summary. Background: The development of malignant tumors, including esophageal cancer (EC), could be associated with impaired expression of oncosuppressive miRNA-200b and еxcision repair cross-complementing group-1 (ERCC1), a protein involved in DNA repair and alternative splicing. Aim: To investigate the features of expression of miRNA-200b and ERCC1 in tumor cells of patients with EC and to determine the possibility of their use for prediction of EC aggressiveness. Materials and Methods: 52 patients with EC of stages II–IV were enrolled. Expression of ERCC1 in tumor cells was assessed by immunohistochemical method, expression of miRNA-200b was evaluated by the real time reverse transcription-polymerase chain reaction. Results: The expression of miRNA-200b and ERCC1 in tumor cells of EC patients is associated with their life expectancy. The characteristic features of neoplasms in patients who died within 12 months are low expression of miRNA-200b (2.87 ± 1.65 a.u.) (ρ = –0.42; p < 0.05) and high expression of ERCC1 (191.0 ± 18.6 H-Score points) (ρ = –0.48; p < 0.05). The inverse correlations between the level of miRNA-200b expression and the tumor size were found both in the group of patients with survival < 12 months (ρ = –0.42; p < 0.05) and in the group of patients with survival > 12 months after surgery (ρ = –0.53; p < 0.05). Conclusions: The obtained data indicate the feasibility of using the expression of miRNA-200b and ERCC1 in EC cells to predict the aggressiveness of esophageal cancer.
References
Malhotra GK, Yanala U, Ravipati A, et al. Global trends in esophageal cancer. J Surg Oncol 2017; 115: 564–79.
Dubrovina N, Gulášová I, Babečka J. Tendencies of the mortality rates from esophageal cancer in the EU countries and Ukraine. Kharkiv Surgical School 2020; 2: 102–7.
Huang FL, Yu SJ. Esophageal cancer: risk factors, genetic association, and treatment. Asian J Surg 2018; 41: 210–5.
Hesari A, Azizian M, Sheikhi A, et al. Chemopreventive and therapeutic potential of curcumin in esophageal cancer: Current and future status. Int J Cancer 2019; 144: 1215–26.
Walterbos NR, Fiocco M, Neelis KJ, et al. Effectiveness of several external beam radiotherapy schedules for palliation of esophageal cancer. Clin Transl Radiat Oncol 2019; 17: 24–31.
Verma V, Moreno AC, Lin SH. Advances in radiotherapy management of esophageal cancer. J Clin Med 2016; 5: 91.
Pöttgen C. Stuschke M. Radiotherapy versus surgery within multimodality protocols for esophageal cancer — a meta-analysis of the randomized trials. Cancer Treat Rev 2012; 38: 599–604.
Chen J, Guo H, Zhai T, et al. Radiation dose escalation by simultaneous modulated accelerated radiotherapy combined with chemotherapy for esophageal cancer: a phase II study. Oncotarget 2016; 7: 22711–9.
Rupaimoole R, Calin GA, Lopez-Berestein G, et al. miRNA deregulation in cancer cells and the tumor microenvironment. Cancer Discov 2016; 6: 235–46.
Kulkarni B, Kirave P, Gondaliya P, et al. Exosomal miRNA in chemoresistance, immune evasion, metastasis and progression of cancer. Drug Discov Today 2019; 24: 2058–67.
Lukianova NYu, Borіkun TV, Bazas VM, et al. Circulating microRNAs: prospects of use for early diagnostics and monitoring of tumor process. Oncologiya 2019; 21: 181–91 (In Ukrainian).
Yang W, Han Y, Zhao X, et al. Advances in prognostic biomarkers for esophageal cancer. Expert Rev Mol Diagn 2019; 19: 109–19.
Zhang HF, Alshareef A, Wu C, et al. miR-200b induces cell cycle arrest and represses cell growth in esophageal squamous cell carcinoma. Carcinogenesis 2016; 37: 858–69.
Park SM, Gaur AB, Lengyel E, et al. The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev 2008; 22: 894–07.
Tang H, Deng M, Tang Y, et al. miR-200b and miR-200c as prognostic factors and mediators of gastric cancer cell progression. Clin Cancer Res 2013; 19: 5602–12.
Feng B, Wang R, Chen LB. Review of miR-200b and cancer chemosensitivity. Biomed Pharmacother 2012; 66: 397–402.
Fareed KR, Al-Attar A, Soomro IN, et al. Tumour regression and ERCC1 nuclear protein expression predict clinical outcome in patients with gastrooesophageal cancer treated with neoadjuvant chemotherapy. Br J Cancer 2010; 102: 1600–7.
Kwon HC, Roh MS, Oh SY, et al. Prognostic value of expression of ERCC1, thymidylate synthase, and glutathione S-transferase P1 for 5-fluorouracil/oxaliplatin chemotherapy in advanced gastric cancer. Ann Oncol 2007; 18: 504–9.
Bellmunt J, Paz-Ares L, Cuello M, et al. Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy. Ann Oncol 2007; 18: 522–8.
Kramer M.F. Stem‐loop RT‐qPCR for miRNAs. Curr Prot Mol Biol 2011; 95: 15–20.
Livak K, Schmittgen T. Analysis of relative gene expression data using real–time quantitative PCR and the 2−∆∆CT method. Methods 2001; 25: 402–8.
Bilen N, Tekin SB, Topdagi O. ERCC1 expression in non-small cell lung and esophageal cancer. Eurasian J Med 2014; 46: 84.
Lord RV, Brabender J, Gandara D, et al. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res 2002; 8: 2286–91.
Neureiter D, Mayr C, Winkelmann P, et al. Expression of the microRNA-200 family, microRNA-205, and markers of epithelial–mesenchymal transition as predictors for endoscopic submucosal dissection over esophagectomy in esophageal adenocarcinoma: A single-center experience. Cells 2020; 9: 486.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Experimental Oncology
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
